Department of Social Sciences, University of Luxembourg, Esch-sur-Alzette, Luxembourg.
Aging Ment Health. 2022 Sep;26(9):1710-1720. doi: 10.1080/13607863.2021.2003297. Epub 2021 Nov 29.
The population of Latin America and Caribbean (LAC) is ageing rapidly, presenting the highest prevalence rates of dementia in the world. Mild cognitive impairment (MCI) is an intermediate condition between normal ageing, Alzheimer's disease, and related dementias. We conducted a systematic review to evaluate the prevalence of MCI in LAC countries and explore factors associated with MCI (i.e. age, sex/gender, and education).
A database search was conducted in September 2020 using PubMed, Web of Science, Scopus, Lilacs, SciELO, EMBASE, and medRxiv for population- or community-based studies, published in English, Spanish, or Portuguese.
From 2,155 screened studies, we selected reports including subjects with a precise diagnosis of MCI. A total of 11 studies met the inclusion criteria, adding up to 20,220 participants in nine countries: Brazil, Mexico, Argentina, Colombia, Peru, Cuba, Dominican Republic, Venezuela, and Costa Rica. Estimates for all-type MCI prevalence ranged from 6.8% to 25.5% and amnestic MCI between 3.1% and 10.5%. Estimates differed by age and education, with oldest and lower-educated adults presenting higher MCI prevalence.
This first systematic review of the prevalence of MCI discusses the population strata with the highest potential to benefit from dementia risk reduction interventions in LAC countries.
拉丁美洲和加勒比地区(LAC)的人口老龄化迅速,是世界上痴呆症患病率最高的地区。轻度认知障碍(MCI)是介于正常衰老、阿尔茨海默病和相关痴呆之间的一种中间状态。我们进行了一项系统评价,以评估 LAC 国家 MCI 的患病率,并探讨与 MCI 相关的因素(即年龄、性别/性别和教育)。
我们于 2020 年 9 月使用 PubMed、Web of Science、Scopus、Lilacs、SciELO、EMBASE 和 medRxiv 对基于人群或社区的研究进行了数据库检索,这些研究发表于英语、西班牙语或葡萄牙语。
在 2155 篇筛选出的研究中,我们选择了包括 MCI 确切诊断的受试者的报告。共有 11 项研究符合纳入标准,涉及来自 9 个国家(巴西、墨西哥、阿根廷、哥伦比亚、秘鲁、古巴、多米尼加共和国、委内瑞拉和哥斯达黎加)的 20220 名参与者。所有类型 MCI 的患病率估计值范围为 6.8%至 25.5%,而遗忘型 MCI 的患病率为 3.1%至 10.5%。估计值因年龄和教育程度而异,年龄最大和受教育程度最低的成年人 MCI 患病率更高。
这是首次对 LAC 国家 MCI 患病率进行的系统评价,讨论了最有可能从痴呆风险降低干预措施中受益的人群。